89 related articles for article (PubMed ID: 20056768)
21. Tumor necrosis factor blockers in rheumatoid arthritis.
Pisetsky DS
N Engl J Med; 2000 Mar; 342(11):810-1. PubMed ID: 10717018
[No Abstract] [Full Text] [Related]
22. Etanercept-induced granulomas: comment on the article by Phillips and Weinblatt.
Hübscher O
Arthritis Rheum; 2006 Apr; 55(2):340; author reply 340-1. PubMed ID: 16583387
[No Abstract] [Full Text] [Related]
23. Pulmonary sarcoidosis developing during infliximab therapy.
O'Shea FD; Marras TK; Inman RD
Arthritis Rheum; 2006 Dec; 55(6):978-81. PubMed ID: 17139647
[No Abstract] [Full Text] [Related]
24. [Pulmonary sarcoidosis developing during treatment with etanercept].
Kerjouan M; Jouneau S; Lena H; Luraine R; Desrues B; Delaval P
Rev Mal Respir; 2011 Mar; 28(3):360-4. PubMed ID: 21482342
[TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
26. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
27. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab.
Almodóvar R; Izquierdo M; Zarco P; Javier Quirós F; Mazzucchelli R; Steen B
Clin Exp Rheumatol; 2007; 25(1):99-101. PubMed ID: 17417999
[TBL] [Abstract][Full Text] [Related]
29. Development of sarcoidosis during etanercept therapy.
González-López MA; Blanco R; González-Vela MC; Fernández-Llaca H; Rodríguez-Valverde V
Arthritis Rheum; 2006 Oct; 55(5):817-20. PubMed ID: 17013853
[No Abstract] [Full Text] [Related]
30. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
31. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
32. [Unnecessary to scare the patients].
Hansen B; Book C
Lakartidningen; 2006 Jan 11-17; 103(1-2):63. PubMed ID: 16465854
[No Abstract] [Full Text] [Related]
33. Do rheumatology cost-effectiveness analyses make sense?
Wolfe F; Michaud K; Pincus T
Rheumatology (Oxford); 2004 Jan; 43(1):4-6. PubMed ID: 14523227
[No Abstract] [Full Text] [Related]
34. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
[TBL] [Abstract][Full Text] [Related]
35. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
36. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
37. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
38. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
39. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
[TBL] [Abstract][Full Text] [Related]
40. TNF inhibition in SLE: where do we stand?
Aringer M; Smolen JS
Lupus; 2009 Jan; 18(1):5-8. PubMed ID: 19074162
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
